Takeda sells generics portfolio to Stada for $660m
German pharmaceutical company Stada Arzneimittel has acquired a portfolio of products from Takeda for $660 million.
In an announcement yesterday, November 5, Stada said the portfolio includes approximately 20 over-the-counter and prescription medicines.
The medicines are currently sold in Russia, Georgia, Azerbaijan, Belarus, Kazakhstan, and Uzbekistan.
Stada said one “key” medicine it has acquired is Cardiomagnyl, a “well-known name in Russia” which is used to prevent blood clots.
It has also acquired patent-protected Nesina (alogliptin), a type II diabetes treatment, and Edarbi (azilsartan), which is used to control blood pressure.
The portfolio also includes vitamins and food supplements.
Stada said it hopes the transaction, which is expected to be completed by the first quarter of 2020, will enable the company to expand its business in Russia.
“The acquired portfolio complements Stada’s existing portfolio and capabilities in Russia which include medicines from 16 of 20 therapeutic groups of the best-selling products in retail pharmacies,” Stada said.
Peter Goldschmidt, CEO of Stada, said it is the company’s largest acquisition to date.
“This transaction also reflects the ambitions of Stada as we continue expanding the business internationally, and continue generating significant operating efficiencies worldwide,” he added.
Did you enjoy reading this story? Sign up to our free daily newsletters and get stories sent like this straight to your inbox.